An open-label study was conducted of nelfinavir mesylate, given with reverse transcriptase inhibitors to human immunodeficiency virus 1 (HIV-1) -infected infants and children 3 months to 13 years of age. Doses of nelfinavir mesylate of 20 -30 mg/kg yielded drug exposures comparable to those seen in adults. The drug was well tolerated; mild diarrhea was the primary toxic effect observed. Seventy-one percent (39) of the 55 evaluable subjects had an initial decrease in plasma HIV-1 RNA, of at least 0.7 log 10 copies/mL; suppression of plasma HIV-1 RNA levels to õ400 copies/mL was observed in 15. Children who began taking at least one new reverse transcriptase inhibitor near the time when nelfinavir mesylate was started, and those with a §24% proportion of CD4 lymphocytes, had a greater chance of achieving and maintaining a decline in plasma HIV-1 RNA to õ400 copies/mL. Suppression of viremia was achieved in children as young as 3 months of age.
HIV type 1 infection is a chronic, active process characterthe HIV-1 Gag and Gag-Pol precursor polyproteins by the protease, resulting in the production of immature, noninfectious ized by constant production and clearance of viral particles and a high rate of loss of CD4
/ lymphocytes [1 -3] . Recently, virus particles. In large multicenter studies involving adults, it was well tolerated and had excellent antiretroviral activity when therapeutic regimens including highly active antiretroviral agents have been demonstrated to suppress virus replication to used in combination with other antiretroviral agents [8] . The current study was designed to evaluate the safety, pharmacokivery low levels for prolonged periods and to decrease morbidity and mortality among both children and adults [4 -6] . Potent netics, and antiretroviral activity of nelfinavir when administered to infants and children. suppression of HIV-1 replication in early infancy has also been associated with normalization of lymphocyte activation markers and, in some cases, with the loss of HIV-1 seropositivity in children [5] . These early results are encouraging, but efforts Methods to effectively treat HIV-1 infection in infants and children have Study design. The study was conducted at four pediatric been limited by the lack of pediatric formulations and the centers in the United States: University of California, Los insufficient amount of pharmacokinetic and toxicity data conAngeles; Bronx Lebanon Hospital Center (Bronx, NY); Unicerning inhibitors of the viral protease and other recently develversity of Massachusetts (Boston); and University of Califoroped antiretroviral agents.
nia, San Diego. The single-dose, intensive pharmacokinetic Nelfinavir mesylate is a nonpeptiditic inhibitor of the HIVphase, in which the powder formulation was used (with plasma 1 protease [7] . Like other such agents, it prevents cleavage of sampling at 0, 2, 4, 6, 8, 12, and 16 hours post-dose), was designed for enrollment of 4 -6 children in each of four age groups: 7 -13 years (group I), 2 -7 years (group II), 3 months enrollments in the younger age groups.
Informed consent for participation was obtained from the parents or guardSingle doses were initiated at 10 mg/kg and were escalated ians of the children enrolled after approval of the study protocol by the instituto achieve group median values for the area under the plasma tional review board at each study site. adults receiving a single 500-mg or 750-mg dose. (At the time tablet formulation, to enable evaluation of the relative bioavaillight meal. Other concomitant antiviral medications were given according to the manufacturers' instructions. ability of the two formulations. Once a group target dose was identified, enrollment in the multiple-dose phase was opened Laboratory studies. Lymphocyte-subgroup analysis, complete blood cell counts, and serum chemistry evaluations were for that group and the study was opened to permit enrollment of an additional cohort directly in the multiple-dose phase, to performed at each site with use of standard methods. Laboratory values were graded according to the Pediatric AIDS Cliniacquire additional safety and efficacy data.
The choice of reverse transcriptase inhibitors during the mulcal Trials Group toxicity table, and marked changes in laboratory values during treatment were defined as shifts from a tiple-dose phase was left to the discretion of the treating physicians, who were encouraged to add (near the time that nelfinavir baseline grade of 0 to grades of 3 or 4, or shifts from a baseline grade of 1 to a grade of 4. Plasma nelfinavir concentrations therapy was initiated) one or more nucleoside analogue reverse transcriptase inhibitors with which a child had had no prior were measured at a central laboratory (PPD Pharmaco, Richmond, VA) by means of a validated HPLC/ultraviolet assay experience. No patients received nonnucleoside reverse transcriptase inhibitors during this study. Addition of new reverse [10] . Separated plasma samples were shipped from the study sites to a central laboratory (Covance, Indianapolis) for meatranscriptase inhibitors was made more difficult in some cases by the unavailability of oral suspension formulations. Patients surement of HIV-1 RNA levels (Roche [Nutley, NJ] Amplicor HIV-1 monitor; lower limit of detection, 400 copies/mL). For were seen 1, 2, 4, and 6 weeks after beginning nelfinavir therapy and then monthly thereafter. Steady-state pharmacokinetic statistical analysis of changes in plasma HIV-1 RNA, a value of 400 copies/mL was assigned to samples below the assay analyses were performed for a subset of children at the week-2 visit, with samples drawn 0, 2, 4, 6, and 8 hours post-dose.
quantification limit. Pharmacokinetic analysis. Nelfinavir plasma C max (maxiAt each visit, an interim history was recorded, a physical examination was performed, and blood samples were collected for mal concentration), t max (time of C max ), and area under the plasma concentration -time curve from 0 to 8 hours (AUC8) or virology and lymphocyte-subset analysis and for safety monitoring.
to infinity (AUCinf) were determined for each pharmacokinetic assessment (AUCinf only, for single-dose assessments). For The protocol and informed consent procedure were reviewed and approved by each institution's human subjects review the week 2 steady-state evaluation, C min represents the trough plasma concentration at 8 hours post-dose. AUC values were board prior to implementation at that site. Enrollment in the single-dose phase began on 27 August 1996, and that in the calculated by the linear trapezoidal method, with extrapolation to infinity for single doses, on the basis of the terminal halfmultiple-dose phase on 24 October 1996. The analysis of adverse events is based on data collected through 4 November life. Pharmacokinetic parameters for the pediatric subjects in this trial were compared to values from similar studies of adults 1997; the analysis of routine laboratory parameters and of the treatment impact on HIV-1 RNA and CD4 lymphocyte subsets receiving nelfinavir alone or in combination with nucleoside analogue reverse transcriptase inhibitors [8] , in the absence of is based on data obtained through 2 December 1997.
Study subjects. HIV-infected children aged 3 months to 13 other drugs known to affect nelfinavir metabolism. Analysis of treatment responses. Baseline values for years and HIV-infected or -exposed infants aged 0 -3 months were eligible for enrollment in this study, regardless of disease plasma HIV-1 RNA concentration and CD4 / lymphocyte parameters were calculated as the means of two pretreatment classification [9], provided the child had no concurrent unstable medical illness or malignancy requiring systemic chemotherapy values. For children enrolled in the single-dose phase, the samples obtained prior to single-dose administration and on day 0 and had not previously received protease inhibitors. Proof of HIV-1 infection included any of the following findings, in of the multiple-dose phase were used in this calculation. For children enrolled directly in the multiple-dose phase, the samtesting performed at a laboratory certified by the AIDS Clinical Trials Group: (1) 2 separate peripheral blood specimens culples obtained during a preenrollment screening visit and on day 0 were used to calculate baseline values. Patients were ture-positive for HIV-1; (2) 1 specimen positive by culture and a separate specimen positive by the HIV-1 DNA PCR assay evaluated for therapeutic responses at each study visit. A change in plasma HIV-1 RNA of §0.7 log 10 copies/mL was or neutralizable-p24-antigen testing; and (3) for children ú15 months of age, 2 separate peripheral blood specimens positive used to classify treatment responses, in accord with recently published guidelines for the use of antiretroviral agents in chilfor HIV-1 antibody by ELISA and western blotting. Six infants were also enrolled on the basis of positive assays for plasma dren [11] . These guidelines reflect the higher degree of variability in HIV-1 RNA levels seen in infants and young children. HIV-1 RNA; ELISA and western blot serology (at §15 months of age) and DNA PCR were used to confirm the diagnosis of This threshold is more stringent than that proposed for the use of viral load assays in the management of HIV infection in HIV-1 infection.
Study medications. Nelfinavir mesylate (Agouron Pharmaadults and adolescents [12, 13] , in whom a 0.5 -0.7-log 10 change is held to be significant. ceuticals, La Jolla, CA) was supplied as 250-mg tablets and as an oral powder (50 mg of nelfinavir per g of powder) to be Treatment responses were classified as (1) undetectable (plasma level of HIV-1 RNA dropped below the limit of detecadministered with milk, infant formula, pudding, water, or a / 9c65$$my46 04-07-99 09:28:27 cida UC: CID tion and remained at that level throughout follow-up); (2) susject age group, baseline percentage of CD4 lymphocytes or plasma viral RNA, or the initiation of treatment with new tained (plasma level of HIV-1 RNA declined by §0.7 log 10 copies/mL from baseline and was maintained throughout folreverse transcriptase inhibitors. The Wilcoxon rank-sum test was used to compare median viral RNA values at week 10. low-up); (3) transient (plasma level of HIV-1 RNA declined by §0.7 log 10 copies/mL from baseline on at least two consecutive measurements but subsequently returned to within 0.7 log 10 Results copies/mL of the baseline value); or (4) none (plasma HIV-1 RNA level did not decline §0.7 log 10 copies/mL from baseline Study populations. Characteristics of the 62 children enrolled in the study are summarized in table 1. One infant enon two consecutive measurements). Single deviations of the viral RNA level to within 0.7 log 10 copies/mL of the baseline rolled in group IV had unacceptably low concentrations of nelfinavir when tested at 7 weeks of age, and treatment with value were permitted in the undetectable and sustained categories to allow for transient rises in plasma level of HIV-1 RNA nelfinavir was therefore discontinued. This infant was reenrolled at 3 months of age in group III, had acceptable nelfinavir as a result of immunization or intercurrent illnesses [13] . In evaluation of possible correlates of virological response, new levels 2 weeks after therapy was resumed, and remained in the study as a group III patient. As only this child was enrolled in nucleoside analogue reverse transcriptase inhibitors were defined as antiretroviral agents that the child had not previously group IV, this report presents data on the 62 children enrolled in groups I -III, aged 3 months to 13 years. Most of the children received and whose administration was initiated within 1.5 months before or 0.5 months after the initiation of treatment were symptomatic or had evidence of immunosuppression.
Mean baseline plasma HIV-1 RNA levels were similar in with multiple-dose nelfinavir. These time frames were selected on the basis of expected time to virological failure of singlegroups II and III and about 3 -5-fold higher than in group I. The higher baseline levels seen in the two younger age groups drug therapy [1 -3] .
Chi-square analysis was used to examine the relationship may reflect both the reported delay in viral-load decline (until age 2 -5 years) in perinatally infected patients [14 -16] and between suppression of viremia to undetectable levels and sub- beginning at or near the time at which thrice-daily dosing of nelfinavir was begun; administration of zidovudine and lamivudine was begun together for nine subjects, and in one case the combined pediatric group (19 patients receiving a mean [{SD] dose of 23 { 3 mg/kg three times daily) and values both stavudine and lamivudine were administered. For the other 22, the change in the reverse transcriptase inhibitor therapy from the pharmacokinetic study of 41 adult subjects with an average weight of 76.3 kilograms ({SD of 10.3) who received consisted of the addition of lamivudine to preexisting therapy with zidovudine or stavudine or the substitution of stavudine 750 mg of nelfinavir three times daily. Figure 1B shows the median plasma concentration -time profile for these same chilfor zidovudine. One patient received no reverse transcriptase inhibitors.
dren and adults. These data demonstrate that nelfinavir concentrations seen in pediatric patients receiving 20 -30 mg/kg per Pharmacokinetics of single-dose nelfinavir. Twenty-three children were enrolled in the single-dose phase: 6 in group I, dose were not significantly different from concentrations in adults receiving 750-mg doses. Thus, on a body weight -ad-11 in group II, and 6 in group III. Sampling profiles of at least 8-hour durations were obtained for only four of the group III justed basis, the young children studied required a nelfinavir dose approximately two to three times higher than that for adult subjects because of the blood-sampling difficulties in this young age group. A comparison of the oral powder and tablet patients to achieve comparable steady-state plasma concentrations. formulations was performed in group I, at doses of 10 mg/kg (n Å 5) and 20 mg/kg (n Å 1). The mean ({SD) powder-toSafety and tolerability. Ten children experienced an adverse event during the single-dose phase of the study, including five tablet ratios for AUCinf (1.04 { 0.39), C max (0.92 { .23), t max (1.17 { 0.68), and terminal half-life (1.00 { 0.55) were close events (all mild) considered by the investigator to be possibly related to nelfinavir: fever, back pain, rash, sweating, and vomto unity, indicating similar pharmacokinetics and oral bioavailabilities for the two formulations.
iting. During the multiple-dose phase, the most common nelfinavir-related toxic effect was diarrhea, occurring in 14 children Single-dose ranging was performed sequentially at dose levels of 10 mg/kg and 20 mg/kg in group I and 10 -30 mg/kg (grade 1 in 13 patients; grade 2 in 1) (table 4) . Ten children's diarrhea was first reported within 1-2 weeks of the start of in group II. The median AUC8 values at 20 mg/kg in these two groups were within the target range of 50% -200% of the multiple-dose nelfinavir treatment; the other patients' diarrhea was first reported at weeks 4, 10, 14, and 30. In the majority median values for a single 500-mg or 750-mg oral dose in adult subjects (table 2). In view of these data, single-dose of cases, diarrhea resolved by the next scheduled visit. Other adverse events considered to be at least possibly related to evaluations for group III children were initiated at 20 mg/kg; the AUC8 values for these children were similar to those for nelfinavir were mild (grade-1) nausea, flatulence, anorexia, epistaxis, fever, neutropenia, abdominal pain, anemia, and gradegroup I patients. Multiple dosing was therefore initiated at 20 -30 mg/kg (three times daily) in all three groups, and children 2 leukopenia/neutropenia. Rash occurred in four patients, including one child with oral rash. Only one child withdrew from in groups I and II were allowed to use either the powder or tablet formulation of nelfinavir, according to the preference of the trial because of an adverse event (grade-2 diarrhea). Marked laboratory-value changes included anemia (2), neutropenia (8), the children and their caretakers.
Multiple-dose-phase pharmacokinetics. Of the 62 children, thrombocytopenia (1), hyperglycemia (1), mild hyponatremia (1), high serum creatinine (1), hyperamylasemia (1), hyperkasteady-state pharmacokinetic profiles were obtained at the week-2 visit for 19: 6 in group I, 10 in group II, and 3 in group lemia (1), and elevated hepatic transaminase (1). These abnormalities were all transient and could not be attributed solely to III. No obvious differences were found in pharmacokinetic parameters across the three age groups; this is reflected in the nelfinavir. Disposition of patients. All 62 patients agreed to participate overlap of steady-state AUC8 values among the children studied (figure 1A). Table 3 lists AUC8, C max , and C min values for in the 6-week multiple-dose phase of the study, with the option / 9c65$$my46 04-07-99 09:28:27 cida UC: CID Effect of treatment on plasma HIV-1 RNA level. Changes to continue to receive nelfinavir during a subsequent extension phase. Seven children (all in groups II and III) left the trial in plasma HIV-1 RNA level were categorized for all 55 children who completed §6 weeks of therapy. The mean plasma viral during the first 6 weeks, because of the difficulty in administering nelfinavir (2), refusal of the agent by the child (1), poor RNA level in all three study groups decreased promptly with the initiation of nelfinavir therapy ( figure 2A) . No virological compliance (1), a parent's request (no explanation given) (2), and loss to follow-up (1). This group included an infant who response was seen in 16 children, including 10 children who had new reverse transcriptase inhibitors added to their therapy. was removed from the study after 2 weeks; he had been given only lamivudine as his sole reverse transcriptase inhibitor, deIn 39 of 55 children (71%), a virological response was seen, defined as a decrease in plasma HIV-1 RNA of §0.7 log 10 spite prescription of stavudine by the study physicians. Seventeen additional children left the study between weeks 10 and 42. copies/mL. In 17 of these 39, only a transient virological response was seen, and plasma HIV-1 RNA values returned to Reasons for discontinuation included increasing or unchanged plasma HIV-1 RNA levels (10), progression of disease (1), within 0.7 log 10 copies/mL of baseline values after a median of 5 weeks in the study (range, 2 -17 weeks). difficulty of administration of nelfinavir (1), parent's choice (3), loss to follow-up (1), and weight loss and diarrhea (the In contrast, in 22 of the 39 responders, a reduction in plasma viral RNA of §0.7 log 10 copies/mL was sustained through the single child with grade-2 diarrhea). The 10 children who left the study because of unchanging or increasing HIV-1 RNA remainder of their follow-up. In 15 of these 22 responders, viral RNA declined to undetectable levels (õ400 copies/mL) levels did so after completing 18 -42 weeks of multiple-dose therapy with nelfinavir (median, 32 weeks); only two of these by 10 weeks of therapy and remained undetectable over periods had had reverse transcriptase inhibitors added to their therapy with the introduction of nelfinavir. Table 4 . Nelfinavir-related treatment-emergent adverse events. of follow-up of up to 54 weeks (median, 42 weeks). The other 2/23 [9%]; P Å .0087). Durable suppression of plasma viral RNA to undetectable levels was also more likely to occur in seven with a sustained response had a mean reduction in plasma HIV-1 RNA value of 1.3 log 10 copies/mL at last follow-up children who had 24% or more CD4 / lymphocytes at baseline (11/27 [41%] vs. 4/28 [14%]; P Å .028). Baseline plasma HIV-(median, 38 weeks; range, 18 -52 weeks). The initial decline in viral RNA level was significantly greater among the subjects 1 RNA value was less well correlated with response; although 6 of the 15 children had baseline levels õ10,000 copies/mL, for whom administration of new reverse transcriptase inhibitors started near the time that nelfinavir was initiated ( figure 2B) the others' were equally distributed between 10,000 -100,000 and §100,000 copies/mL, with 1 child exhibiting a baseline (median week-10 log 10 viral RNA values of 2.84 vs. 4.32; P Å .0083 by Wilcoxon's rank-sum test).
level ú1 million copies/mL. The baseline RNA value of children who achieved and maintained viral RNA levels õ400 Characteristics of infants and children in whom an undetectable plasma HIV-1 RNA level (õ400 copies/mL) was achieved copies/mL was not significantly different from that of children with lesser responses to therapy during the study (P Å .180). and maintained throughout the period of follow-up are summarized in pharmacokinetics, and the data presented in this report are
One or more 13 19 based upon studies performed after an observed dose administered under standardized conditions. Additional studies are un-NOTE. NRTI Å nucleoside analog reverse transcriptase inhibitor.
der way to determine nelfinavir dose requirements for children õ3 months of age and to determine if doses ú750 mg three times daily might be appropriate for children with body weights count was seen; this may reflect the normal developmental of §25 kg for whom a dose of 30 mg/kg exceeds 750 mg. decrease seen in this age range [17] . Mean changes from baseAlthough this study was not specifically designed to evaluate line percentages of CD4 lymphocytes were similar across age treatment efficacy, we found evidence of potent antiretroviral groups, and the peak increase of 7% -8% was observed at week activity of the combination of nelfinavir and reverse tran-26 (figures 3A and 3B). The greatest long-term increases in scriptase inhibitors in children. A significant (ú0.7 log 10 ) re-CD4 lymphocyte percentages occurred in patients in whom an duction in plasma viral RNA was seen in most subjects. Alundetectable level of HIV-1 RNA was achieved and sustained.
though this response was transient in 43% (17 of the 39 with These patients had a higher mean percentage at baseline (29%) an initial response), plasma HIV-1 RNA levels were reduced and achieved a mean increase of 3% -7% throughout most to below the limit of detection in children as young as 3 months of the period of follow-up ( figure 3C) ; patients in whom an of age, including subjects with baseline plasma viral RNA undetectable plasma HIV-1 RNA level was not achieved or levels as high as 1 million copies/mL. maintained had a lower mean percentage at baseline (22%) and Virological response was not correlated with baseline viral showed little change over the course of the study.
load, but the wide variation in the age, level of immunosuppression, and prior therapy may have obscured a relationship among these variables. Prolonged suppression of plasma viremia was Discussion observed more often when administration of new reverse transcriptase inhibitors was initiated in conjunction with nelfinavir This study demonstrates that the combination of nelfinavir and nucleoside analogue reverse transcriptase inhibitors is well therapy and in patients with higher baseline CD4 lymphocyte percentages. In this study, the greatest changes in CD4 / lymtolerated for prolonged periods by HIV-1-infected children and exhibits better antiviral activity when new reverse transcriptase phocyte values were observed in patients in whom an undetectable viral load was achieved and maintained. However, even inhibitors are simultaneously added to the patient's therapy. The cohort of children studied consisted largely of those with a modest sustained decrease in HIV-1 load has been associated / 9c65$$my46 04-07-99 09:28:27 cida UC: CID / lymphocytes in subjects with and without prolonged suppression of plasma HIV RNA levels to below the limit of detection (400 copies/mL).
with immunologic improvement and delayed progression of may develop with progressive HIV-1 infection [12] . Clearly, suboptimal responses to nelfinavir mesylate may also have redisease in children with symptomatic HIV-1 infection [23, 24] .
Although the simultaneous introduction of multiple new sulted from insufficient drug exposure due to inadequate dosing, inadequate absorption, increased clearance or metabolism, drugs is a necessary condition for maximal suppression of viral replication, it is frequently not a sufficient condition, as only and especially poor adherence to the therapeutic regimen. Although accounting for medication dispensed and returned transient reductions in plasma HIV-1 RNA levels were seen in many subjects. The response in patients with lower percentwas incorporated into this study to identify patients who clearly were not compliant with the protocol for nelfinavir use, no ages of CD4 lymphocytes was smaller, which may reflect the more advanced state of disease in these patients. The failure rigorous measures of adherence to the therapy were compiled; this may represent a limitation of our study. In view of the low of antiretroviral therapy to suppress virus replication in these subjects could be related to evolution of the virus to greater incidence of toxicity observed in this study, it may be feasible to administer even higher doses of this protease inhibitor to pathogenicity, broad resistance to antiretroviral agents, wider entrenchment of virus in sanctuary sites, or other changes that increase drug exposure and improve virological responses. Fur-/ 9c65$$my46 04-07-99 09:28:27 cida UC: CID
